Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antiprotozoal (antimalarial) presented as a 250 mg atovaquone / 100 mg proguanil hydrochloride tablet for oral use. It prevents and treats malaria caused by Plasmodium falciparum, vivax, malariae, and ovale in travelers and patients who need therapy.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is used in the prevention and treatment of malaria, an infection caused by Plasmodium parasites.

- Prophylaxis of malaria: prevents infection in travelers to endemic regions. - Treatment of acute uncomplicated malaria: clears parasites in patients with confirmed infection. - Post‑exposure prophylaxis: used after possible exposure when immediate treatment is not feasible.

Malarone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal pain: cramp‑like discomfort. - Headache: transient headache. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Hematologic abnormalities: neutropenia or anemia.

Before prescribing Malarone, consider the following safety measures.

- Pregnancy: Category B; use only if the benefit outweighs the potential risk. - Breastfeeding: caution, as the drug may be excreted in milk. - Renal impairment: dose adjustment may be required; monitor renal function. - G6PD deficiency: monitor for signs of hemolysis. - Concomitant antiretrovirals: may reduce efficacy; assess alternative regimens. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Malarone can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Rifampin: induces metabolism and markedly reduces atovaquone concentrations. - Protease inhibitors (e.g., ritonavir): may lower atovaquone exposure, compromising efficacy. - St. John’s wort: enzyme induction can decrease drug levels.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Digoxin: atovaquone can raise serum digoxin levels; check concentrations. - Cimetidine: may elevate proguanil levels, increasing risk of toxicity.